

# *Practical Tips for Deprescribing in Older Adults*

Sunny Linnebur, PharmD, BCGP, BCPS, FCCP, FASCP  
Professor  
Skaggs School of Pharmacy and Pharmaceutical Sciences  
sunny.linnebur@cuanschutz.edu



1

---

---

---

---

---

---

---

---

## **Disclosure Slide**

- Dr. Linnebur has the following conflicts of interest related to this presentation:
  - ✓ Dr. Linnebur is a member of the Expert Panel for the 2023 Updated AGS Beers Criteria® and was a member of the 2019, 2015, and 2012 expert panels



2

---

---

---

---

---

---

---

---

## **Objectives**

- Apply shared decision-making principles and strategies when deprescribing
- Incorporate deprescribing pathways into clinical treatment plans
- Utilize online tools to effectively deprescribe



3

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

4




---

---

---

---

---

---

---

---

5

- ### Treatment Decisions in Older Adults
- Consider goals of care
    - ✓ How frail is the patient?
    - ✓ Is the patient more interested in palliative care or prevention meds/tx?
    - ✓ What are the patient's QOL goals?
  - Consider time to benefit: the time between when an intervention is initiated & when improved health outcomes occur
  - To identify which patients are more likely to be helped vs harmed
    - ✓ Compare time to benefit vs life expectancy
- Lee SJ, Leipzig RM, Walter LC. JAMA 2013;310(24):2669-10. Br J Gen Pract 2017; DOI: <https://doi.org/10.3399/bjgp17X690533>

---

---

---

---

---

---

---

---

6



## ADA Algorithm: Simplification of Complex Insulin Therapy

- Change timing of basal insulin from evening to morning
- Stop sliding scale insulin
- How to titrate basal insulin based on fasting blood glucose
- How to stop mealtime insulin and start non-insulin options to replace it
  - ✓ Examples: metformin, GLP-1 agonists, DPP4-inhibitors, SGLT-2 inhibitors, pioglitazone
- Make changes to insulin regimen every 1-2 weeks

[https://care.diabetesjournals.org/content/44/Supplement\\_1/S168](https://care.diabetesjournals.org/content/44/Supplement_1/S168)

10

---

---

---

---

---


---

---

---

## Drugs to Consider Deprescribing

- Never necessary medications
- Indicated but not beneficial medications
- No longer necessary medications
- Unnecessary OTC meds and supplements
- Drugs causing side effects
- Drugs that the patient is interested in stopping
- Trade drugs for non-pharmacologic approaches



[www.lovwinstitute.org/pills](http://www.lovwinstitute.org/pills)

11

---

---

---

---

---

---

---

---

## "Never Necessary Prescribing"

- **Drugs with a high risk and low benefit or with safer alternatives**
  - ✓ Example: Drugs on the AGS Updated Beers Criteria®
- **Drugs that are intended to be short-term but are continued long-term**
  - ✓ Examples: PPIs for ulcer ppx or treatment; Albuterol inhaler for an acute respiratory infection
- **Drugs initiated as part of the prescribing cascade**

12

---

---

---

---

---

---

---

---

# 2023 Updated AGS Beers Criteria®...Coming Soon

13

---

---

---

---

---

---

---

---

# The Prescribing Cascade



14

---

---

---

---


---

---

---

---

# Prescribing Cascade Example



JAMA Intern Med. 2020;180(5):643-651. doi:10.1001/jamainternmed.2019.7087

15

---

---

---

---

---

---

---

---

## Avoiding the Prescribing Cascade

- For any new symptoms, if reasonable investigate drug causes 1<sup>st</sup>!
  - ✓ Ask your pharmacist to review drug databases and 1<sup>o</sup> literature
  - ✓ Many side effects are predictable and easy to identify
  - ✓ Rare side effects often occur in older adults
- Review for temporal relationship
- Laboratory measurements may be helpful
- Discontinue the drug or reduce the dose and monitor for symptom resolution
- If necessary, consider drug rechallenge



16

---

---

---

---


---

---

---

---

## Other Prescribing Cascade Examples



17

---

---

---

---

---

---

---

---

## “Indicated but Not Beneficial Prescribing”

- **Drugs that have lost their effects or only provide modest benefit**
  - ✓ Example: dementia meds, sulfonylureas, antimuscarinics for UI
- **Drugs that will not be effective or show benefit in the remaining life span of the patient**
  - ✓ Example: statin for primary prevention
- **Drugs that have drug-drug interactions so they are not absorbed**
  - ✓ Examples: PPI + calcium carbonate/bisacodyl/clopidogrel



18

---

---

---

---

---

---

---

---

## “No Longer Necessary Prescribing”

- **Drugs indicated for a certain time frame but never stopped**
  - ✓ Examples: bisphosphonates, anticoagulants, antiplatelets, PPIs, antidepressants, metoclopramide, estrogen
- **Drugs no longer necessary due to changes in goals of care**
  - ✓ Examples: bisphosphonates, statins, ASA, dementia meds, vitamins and minerals (e.g. calcium, vit D, vit B12)
- **Drugs used to treat a condition too aggressively**
  - ✓ Examples: DM or HTN treatment

19

---

---

---

---

---

---

---

---

## “Unnecessary OTC and Supplement Use”

- | <u>Can cause harm</u>    | <u>Often no long-term indication or data</u> |
|--------------------------|--|
| ➤ Aspirin                | ➤ Multivitamins                              |
| ➤ Ibuprofen and naproxen | ➤ Fish oil                                   |
| ➤ Diphenhydramine        | ➤ Probiotics                                 |
| ➤ Pseudoephedrine        | ➤ Vitamin C                                  |
| ➤ Omeprazole/PPIs        | ➤ Almost everything else                     |

EXCEPTIONS: vitamin D and B12, folate, calcium, iron, melatonin, diclofenac gel, acetaminophen, and AREDS2

<https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2781119>

20

---

---

---

---

---


---

---

---

## Trade Drugs for Non-Pharmacologic Approaches

- Counseling/cognitive behavioral therapy/virtual reality
- Facility activities/social events
- Music therapy
- Physical therapy
- Exercise
- Heat/ice



21

---

---

---

---

---

---

---

---

## Deprescribing Tips and Tools

Starting medications is like the bliss of marriage and stopping them is like the agony of divorce...



--Doug Danforth

22

---

---

---

---

---

---

---

---

## General Tips to Overcome Barriers to Deprescribing

- Add in prescription drug checkups to visits
  - ✓ Perform after hospitalizations as well
- View discontinuation of drugs as part of the normal prescribing process and use shared decision making
  - ✓ Discuss options with patient/family and rationale for deprescribing, consider discussion of side effects and changes associated with aging
    - Continuation may cause harm
    - Discontinuation may cause harm
  - ✓ Educate patient/family and monitor for harm

23

---

---

---

---

---

---

---

---

## Common Drugs To Consider Deprescribing

- |                          |                             |
|--------------------------|-----------------------------|
| ✓ Proton pump inhibitors | ✓ Sedative hypnotics        |
| ✓ Benzodiazepines        | ✓ Antipsychotics            |
| ✓ NSAIDs                 | ✓ Statins                   |
| ✓ Anticholinergics       | ✓ ASA                       |
| ✓ Insulin                | ✓ Cholinesterase inhibitors |
| ✓ Sulfonylureas          | ✓ Memantine                 |
|                          | ✓ OTCs/supplements          |

24

---

---

---

---

---

---

---

---



## To Taper or Not to Taper?

### Best to Taper

- Beta-blockers
- Clonidine
- Benzodiazepines
- Antidepressants
- Antipsychotics
- Opioids
- Pregabalin/gabapentin
- Proton pump inhibitors
- Estrogen

### Generally No Taper Needed

- ACE-Is, ARBs, diuretics
- Statins
- Anticholinergics
- NSAIDs and aspirin
- Insulin, sulfonylureas, metformin
- Cholinesterase inhibitors
- OTCs and supplements



25

---

---

---

---

---

---

---

---

---

---

[www.deprescribing.org](http://www.deprescribing.org)  
[www.deprescribingnetwork.ca](http://www.deprescribingnetwork.ca)

- Deprescribing educational tools for patients and caregivers
- Deprescribing algorithms and videos for clinicians
- Deprescribing patient decision aids
- Non-drug advice
  
- PPIs, benzodiazepines, Z-drugs, antihyperglycemic agents, antipsychotics, cholinesterase inhibitors/memantine
- Studies: JAMA Intern Med. 2014;174(6):890-898. J Am Geriatr Soc 2018;66:1186-1189



26

---

---

---

---

---

---

---

---

---

---

**You May Be at Risk**  
 You are taking one of the following sedative-hypnotic medications:

<input type="checkbox"/> Alprazolam (Xanax)	<input type="checkbox"/> Oxazepam (Serenid)	<input type="checkbox"/> Temazepam (Restoril)
<input type="checkbox"/> Bromazepam (Lexipam)	<input type="checkbox"/> Eszopiclone (Lunesta)	<input type="checkbox"/> Triazolam (Halcion)
<input type="checkbox"/> Clonazepam (Klonopin)	<input type="checkbox"/> Lorazepam (Ativan)	<input type="checkbox"/> Zolpidem (Ambien)
<input type="checkbox"/> Clonazepam (Klonopin)	<input type="checkbox"/> Lorazepam (Ativan)	<input type="checkbox"/> Zolpidem (Ambien)
<input type="checkbox"/> Clonazepam (Klonopin)	<input type="checkbox"/> Lorazepam (Ativan)	<input type="checkbox"/> Zolpidem (Ambien)
<input type="checkbox"/> Clonazepam (Klonopin)	<input type="checkbox"/> Lorazepam (Ativan)	<input type="checkbox"/> Zolpidem (Ambien)
<input type="checkbox"/> Clonazepam (Klonopin)	<input type="checkbox"/> Lorazepam (Ativan)	<input type="checkbox"/> Zolpidem (Ambien)
<input type="checkbox"/> Clonazepam (Klonopin)	<input type="checkbox"/> Lorazepam (Ativan)	<input type="checkbox"/> Zolpidem (Ambien)

CoDeN

### SO ASK YOURSELF:

#### YES OR NO?

- Have you been taking this sedative-hypnotic drug for a while?  Y  N
- Are you often tired and groggy during the day?  Y  N
- Do you ever feel hungover in the morning, even though you have not been drinking?  Y  N
- Do you ever have problems with your memory or your balance?  Y  N

#### AS YOU AGE

Age-related changes take place in your body and modify the way you process medications. Drugs stay in your body longer and diminished liver function and poor blood flow to your kidneys may increase side effects. The chances you will take more than one medication increases as you age, as does your likelihood of having multiple chronic illnesses.

Unfortunately, this important information is often not passed on to patients who are taking this drug. Please consult your doctor, nurse or pharmacist to discuss this further. Alternative therapies could relieve your anxiety or improve your sleep with fewer side effects and improved quality of life.

[www.deprescribingnetwork.ca](http://www.deprescribingnetwork.ca)

8.



27

---

---

---

---

---

---

---

---

---

---

**DEPRESCRIBING: REDUCING MEDICATIONS SAFELY TO MEET LIFE'S CHANGES**

As life changes, your medication needs may change as well. Medications that were once good for you may not be the best choice for you now. Deprescribing is a way for health care providers to help you safely cut back on medications.

**WHAT ARE BENZODIAZEPINE RECEPTOR AGONISTS & Z-DRUGS (BZRAs)?**

- Drugs used to treat problems like anxiety or difficulty sleeping
- Examples include:
  - Alprazolam (Xanax)<sup>®</sup>
  - Clonazepam (Klonopin)<sup>®</sup>
  - Lorazepam (Ativan)<sup>®</sup>
  - Oxazepam (Serenid)<sup>®</sup>
  - Temazepam (Restoril)<sup>®</sup>
  - Zolpidem (Ambien)<sup>®</sup>
  - Zolpidem CR (Ambien CR)<sup>®</sup>
  - Zolpidem XR (Ambien XR)<sup>®</sup>
  - Zopiclone (Zovance)<sup>®</sup>

**WHY CONSIDER REDUCING OR STOPPING A BZRA BEING USED FOR INSOMNIA?**

- BZRAs can cause dependence
- BZRAs may be prescribed for short-term problems, but can become long-term use
- BZRAs may become habit-forming after only a few weeks
- BZRAs are not recommended at all ages (less of benefit in older people)
- BZRAs may become less helpful for older people after only a few weeks

**HOW TO SAFELY REDUCE OR STOP A BZRA**

- Ask your health care provider to find out if deprescribing is for you. BZRA doses should be reduced slowly with supervision.
- Tell your health care provider about the BZRA deprescribing algorithm, available online: <https://depressingresearch.org/benzodiazepine-and-z-drug-deprescribing-algorithm/>
- Download the BZRA patient information pamphlet, available online: <https://depressingresearch.org/benzodiazepine-and-z-drug-deprescribing-patient-information-pamphlet/>

Ask questions, stay informed and be proactive.

depressingresearch.org

28

---

---

---

---

---

---

---

---

---

---

---

---

depressing.org | Benzodiazepine & Z-Drug (BZRA) Deprescribing Algorithm

Why is patient taking a BZRA?

If anxious, seek out if history of anxiety, past psychiatric consult, whether may have been started in hospital for sleep, or for pain management.

**Engage patients** Discuss potential risks, benefits, withdrawal plan, symptoms and disorders

**Recommend Deprescribing**

**Taper and then stop BZRA**

- Taper over 12 weeks in inpatient setting (average 12% were taper weeks, and if possible, 12.5% reductions near and/or missed drug free days)
- For those ≥ 65 years of age: strong recommendation from systematic review and LMHC approach
- For those 18-64 years of age: weak recommendation from systematic review and LMHC approach
- Offer behavioural sleeping advice; consider CBT if available (see reverse)

**Monitor every 1-2 weeks for duration of tapering**

Expected benefits:

- May improve alertness, cognition, daytime sedation and reduce falls

Withdrawal symptoms:

- Irritability, anxiety, insomnia, sweating, gastrointestinal symptoms (all usually mild and last for days to a few weeks)

Use non-drug approaches to manage symptoms

Use behavioral strategies (CBT or CBTi) (see reverse)

If symptoms relapse:

- Consider:
  - Monitoring current BZRA dose for 1-2 weeks, then continue to taper at slow rate
  - Alternate drugs
  - Consider mood stabilizers (see reverse) to manage symptoms
  - Consider assessment of their ability and effectiveness to repeat the steps of the algorithm. See BZRA deprescribing guideline for details.

depressing.org | Bruyère | OPEN

29

---

---

---

---

---

---

---

---

---

---

---

---

**US Deprescribing Research Network (USDeN)**

- <https://depressingresearch.org/>
- Links to Canadian, Australian, and UK deprescribing tools
- Links to articles discussing deprescribing and potentially inappropriate medications
- Webinars for researchers and clinicians

30

---

---

---

---

---

---

---

---

---

---

---

---

## MedStopper.Com

- Provides guidance for deprescribing with risk/benefit for each drug
- Medications can be arranged by either stopping priority or by condition
- For some medications/indications, just below the faces, there are CALC and NNT links for more information.
- Includes suggested tapering approach if applicable
- If the medication is listed in either the Beers or STOPP criteria, click the details button and the specific criteria form these tools will be provided in a popup

31

---

---

---

---

---

---

---

---

## MEDSTOPPER.COM

Stopping Priority RECOMMENDATION GREEN/LOWEST	Medication/ Category/ Condition	May Improve Symptoms?	May Reduce Risk for Future Illness?	May Cause Harm?	Suggested Taper Approach	Possible Symptoms when Stopping or Tapering	Beers/STOPP Criteria
	gabapentin gabapentin neuropathic pain	😊	😐	😐	If used daily for more than 2-4 weeks. Reduce dose by 25% every week (i.e. week 1: 20%, week 2: 50%, week 3: 75%) and this can be extended or abbreviated (10% dose reductions) if needed. If intolerable withdrawal symptoms occur (usually 1-3 days after a dose change), go back to the previously tolerated dose until symptoms resolve and pain for a more gradual taper with the patient. Dose reduction may need to slow down as one goes to smaller doses (i.e. 25% of the original dose). Overall, the rate of discontinuation needs to be controlled by the person taking the medication.	return of symptoms, pain	None

32

---

---

---

---

---

---

---

---

## TaperMD (taperMD.com)

- Medication Therapy Management and Drug Review Tool (for a fee)
  - ✓ Dashboard with EHR integration with PointClickCare
  - ✓ Tracking and exporting of reports related to patient progress, recommendations, and monitoring plan
- Deprescribing resources: guidelines, algorithms, guides for many drugs (free)
- Taper guidance, withdrawal symptoms and monitoring guidance for many drugs (free)

33

---

---

---

---

---

---

---

---

**MedSafer** <https://www.medsafer.org/>

➤ Deprescribing software integrated with PointClickCare in Canada

**ORIGINAL RESEARCH**

**MedSafer to Support Deprescribing for Residents of Long-Term Care: a Mixed-Methods Study**

Giulia Anna Perri, MD<sup>1</sup>, Emilia Bordehain-Corval, MD<sup>2</sup>, Christopher D. Britton, MD<sup>1</sup>, Anna Baril, MD<sup>1</sup>, Anna Theresa Santiago, MD, PhD<sup>1</sup>, Marie Morin, MD, PhD<sup>1</sup>, Todd C. Lee, MD, PhD<sup>1</sup>, Emily G. McDonald, MD, PhD<sup>1</sup>

<sup>1</sup>Baycrest, Toronto, ON; <sup>2</sup>Faculty of Medicine and Health Sciences, Division of Experimental Medicine, McGill University, Montreal, QC; <sup>3</sup>Clinical Practice Assessment Unit, McGill University Health Centre, Montreal, QC; <sup>4</sup>Clinical Pharmacy, Edmonton, AB

\*These authors contributed equally to this paper

https://doi.org/10.2776/2022.242

JAMA Internal Medicine | Original Investigation | LESS IS MORE

**The MedSafer Study—Electronic Decision Support for Deprescribing in Hospitalized Older Adults: A Cluster Randomized Clinical Trial**

Emily G. McDonald, MD, PhD, Peter E. Hu, MD, PhD, Babak Farhad, MD, MPH, Marie-Claude Rivest, MD, MPH, Emilia Bordehain-Corval, MD, PhD, Anna Baril, MD, PhD, Scott D. Hill, MD, PhD, Scott Brown, MD, PhD, Leah Stewart, MD, PhD, Jonathan Hogg, MD, PhD, Louise Fugère-Fortin, MD, PhD, Louise Pilon, MD, PhD, Sandra Parker, MD, PhD, Jolanda Kuzma, MD, PhD, Robert B. Kim, MD, PhD, Jennifer Wu, MD, PhD, Victor Santiago, MD, PhD, Marie Morin, MD, PhD, Jean-François Lévesque, MD, PhD, Thomas J. Moore, MD, PhD, Scott D. Hill, MD, PhD, Emily A. Markson, MD, PhD, James Downer, MD, MPH, Alan F. Huang, MD, PhD, Thomas J. Moore, MD, PhD, George B. Carreras, MD, PhD, Todd C. Lee, MD, PhD

https://jamanetwork.com/journals/ama/internalmedicine/fullarticle/3778829  
8297: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116642/



---

---

---

---

---

---

---

---


---

---

34

**Example Deprescribing**

**89 y/o man with dementia and atrial fibrillation**



---

---

---

---

---

---

---

---


---

---

35

**Deprescribing Considerations for Each Drug**

- ✓ Is the patient receiving a benefit from the drug?
- ✓ Do the harm(s) outweigh the benefit?
- ✓ Are the patient's symptoms stable?
- ✓ Is the purpose of the drug preventive or treatment?
- ✓ Will withdrawal symptoms or disease recurrence occur if the drug is stopped?
- ✓ Is tapering required?
- ✓ How should the patient be monitored?



---

---

---

---

---

---

---

---

---

---

36

## Deprescribing Process

- 1. Review medications for opportunities to deprescribe. You identify simvastatin 40 mg and omeprazole 20 mg daily.
  - ✓ Statin indication: primary prevention of CV events, no stroke history
  - ✓ PPI indication: GERD, patient currently asymptomatic
- 2. Consider life expectancy and using eprognosis



37

---

---

---

---

---

---


---

---

---

---

## Deprescribing Process



38

---

---

---

---

---

---

---

---

---

---

## Deprescribing Process

- 3. Consider benefits
  - ✓ Less pill burden, less muscle pain, less GI side effects, less DDIs, lower risk of C. diff/PNA/Mg and B12 deficiency
- Consider risks
  - ✓ Return of GI symptoms; potential increased GI bleed risk if patient is taking a DOAC or ASA
  - ✓ CV events—3 retrospective studies of older adults show ↑ CV risk 2-5 yrs after discontinuation, no increased risk if at end of life
- 4. Do the meds need tapered?
  - ✓ PPI: ideally, yes
  - ✓ Statin: no



39

---

---

---

---

---

---

---

---

---

---

## Deprescribing Process

- 5. Discontinue simvastatin
- 6. Consider omeprazole taper <https://tapermd.com/tapering-resources/proton-pump-inhibitors/>
  - ✓ Reduce dose by 50% every 1-2 weeks. Once at 25% of the original dose and no withdrawal symptoms have been seen, stop the drug
  - ✓ If any withdrawal symptoms occur, go back to approximately 75% of the previously tolerated dose
- 7. Construct and document a follow-up plan
  - ✓ Monitor for CV events?: no
  - ✓ Monitor for side effect (GI/muscle pain) resolution: yes
  - ✓ Monitor for return of GERD/heartburn: yes

40

---

---

---

---

---

---


---

---

---

---

Figure 1 | Proton Pump Inhibitor (PPI) Deprescribing Algorithm



41

---

---

---

---

---

---

---

---

---

---

# THANK YOU! QUESTIONS?

Sunny.Linnebur@CUAnschutz.edu

42

---

---

---

---

---

---

---

---

---

---